Literature DB >> 9524295

Reactivity of chagasic antigal antibodies with noninfected cells treated with Trypanosoma cruzi secreted/excreted antigens.

J K Yokoyama-Yasunaka1, R M Piazza, E S Umezawa, A M Stolf.   

Abstract

Here, we show that antigal antibodies from Chagas' disease patients react with noninfected host cells previously treated with antigens secreted by the trypomastigote forms of Trypanosoma cruzi. With the exception of human and Old World monkey cells, which are GAL-negative, cells of all mammals express the GAL epitope (Gal alpha (1-3)Gal beta (1-4)GlcNAc-R) on their surface. Thus only the former ones develop antigal antibodies. Antigal antibodies increase during infection with T. cruzi, which expresses GAL epitopes on the surface of the infective forms. Here, we show that incubation of noninfected, GAL-negative cells with antigens shed by T. cruzi renders these cells reactive to antigal antibodies purified from chagasic sera. Neither chagasic sera depleted of antigal antibodies nor antigal antibodies purified from normal sera display reactivity with treated cells. Cell reactivity of chagasic antigal was abolished in the presence of melibiose (Gal alpha (1-6)Glc) or gal-gal (methyl 3-O-alpha-D-galactopyranosyl alpha-D-galactopyranoside). Since shedding of T. cruzi antigens can occur in vivo, these antigens may induce reactivity of chagasic antigal with noninfected human cells. The reactivity of noninfected, GAL-negative cells observed only with chagasic antigal antibodies can amplify the range of reactivity of these antibodies and consequently adds to their importance in the pathogenesis of human Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9524295      PMCID: PMC6807917     

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  35 in total

1.  Trypanosoma cruzi: shedding of surface antigens as membrane vesicles.

Authors:  M F Gonçalves; E S Umezawa; A M Katzin; W de Souza; M J Alves; B Zingales; W Colli
Journal:  Exp Parasitol       Date:  1991-01       Impact factor: 2.011

2.  Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3.

Authors:  R Hoess; U Brinkmann; T Handel; I Pastan
Journal:  Gene       Date:  1993-06-15       Impact factor: 3.688

Review 3.  The acid-active hemolysin of Trypanosoma cruzi.

Authors:  N W Andrews
Journal:  Exp Parasitol       Date:  1990-08       Impact factor: 2.011

4.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

5.  Electrophoretic detection of Trypanosoma cruzi peptidases.

Authors:  S Greig; F Ashall
Journal:  Mol Biochem Parasitol       Date:  1990-02       Impact factor: 1.759

Review 6.  Carbohydrate immunity in American trypanosomiasis.

Authors:  L R Travassos; I C Almeida
Journal:  Springer Semin Immunopathol       Date:  1993

7.  Determination of total protein.

Authors:  G L Peterson
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

8.  Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease.

Authors:  E S Umezawa; M S Nascimento; N Kesper; J R Coura; J Borges-Pereira; A C Junqueira; M E Camargo
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

9.  Changes in isotype composition and antigen recognition of anti-Trypanosoma cruzi antibodies from acute to chronic Chagas disease.

Authors:  E S Umezawa; M A Shikanai-Yasuda; A M Stolf
Journal:  J Clin Lab Anal       Date:  1996       Impact factor: 2.352

10.  Glycoconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas disease.

Authors:  I C Almeida; G M Krautz; A U Krettli; L R Travassos
Journal:  J Clin Lab Anal       Date:  1993       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.